Drugs / Arotinolol
Arotinolol
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 42 trials | ||||||
| Phase 4 | NCT02612298 | Aug 2015 → Sep 2018 | essential hypertension | Marubeni Pharmaceuticals (Suzhou) Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT01351636 | Apr 2011 → Oct 2018 | chronic kidney disease | Marubeni Pharmaceuticals (Suzhou) Co., Ltd. | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06780865 | Jan 2025 → Dec 2028 expected | chronic kidney disease, secondary hypertension | Shanghai Institute of Hypertension | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Arotinolol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02612298 ↗ |
| Known as | Arotinolol Hydrochloride | “Arotinolol Hydrochloride, oral, 5-15mg, bid for 12 weeks” NCT02612298 ↗ |
| Known as | NSC-317940 | ChEMBL registry synonym — accepted as the source's own label CHEMBL93298 ↗ |
| Modality | Small molecule | — CHEMBL93298 ↗ |
| Route | Oral | “Arotinolol Hydrochloride, oral, 5-15mg, bid for 12 weeks” NCT02612298 ↗ |